

1 Prevalence of Bacterial Coinfection and Patterns of Antibiotics
2 Prescribing in Patients with COVID-19: A Systematic review and
3 Meta-Analysis
4

5
6 Faisal Salman ALSHAIKH^{a,b}, Oula Nawaf SINDI^a, Brian GODMAN^{a,c,d}, R Andrew
7 SEATON^{d,e}, Amanj KURDI^{g,h,a,d}

8
9 ^a Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of
10 Strathclyde, Glasgow, UK; ph.faisalalshaikh@gmail.com; oula.nawaf@gmail.com

11 ^b Pharmaceutical Services, Bahrain Defence Force Military Hospital, Kingdom of Bahrain

12 ^c Centre of Medical and Bio-allied Health Sciences Research, Ajman University, United Arab
13 Emirates

14 ^dDivision of Public Health Pharmacy and Management, School of Pharmacy, Sefako
15 Makgatho Health Sciences University, Pretoria, South Africa

16 ^eQueen Elizabeth University Hospital, Glasgow, UK

17 ^fScottish Antimicrobial Prescribing Group, Healthcare Improvement Scotland, Glasgow, UK

18 ^gCenter of Research and strategic studies, Lebanese French University, Erbil, Kurdistan

19 Region Government, Iraq

20 ^hDepartment of Pharmacology and Toxicology, College of Pharmacy, Hawler Medical
21 University, Erbil, Kurdistan Region Government, Iraq

22
23
24
25
26
27 **Corresponding Author:**

28
29 Faisal Alshaikh

30
31 Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, 161
32 Cathedral Street, Glasgow, G4 0RE, Scotland, UK

33
34 **Email:** ph.faisalalshaikh@gmail.com

35 **Telephone:** (00973)36805888

36
37 **Co-corresponding Author:**

38
39 Brian Godman

40
41 **Email:** briangodman@outlook.com

42
43 **Word Count:** 3583

44
45 **Number of Tables:** 1

46
47 **Number of Figures:** 7

49

50 Abstract

51

52 *Background:* Evidence around prevalence of bacterial coinfection and pattern of antibiotic
53 use in COVID-19 is controversial although high prevalence rates of bacterial coinfection
54 have been reported in previous similar global viral respiratory pandemics. Early data on the
55 prevalence of antibiotic prescribing in COVID-19 indicates conflicting low and high
56 prevalence of antibiotic prescribing which challenges antimicrobial stewardship programmes
57 and increases risk of antimicrobial resistance (AMR).

58 *Aim:* To determine current prevalence of bacterial coinfection and antibiotic prescribing in
59 COVID-19 patients

60 *Data Source:* OVID MEDLINE, OVID EMBASE, Cochrane and MedRxiv between January
61 2020 and June 2021.

62 *Study Eligibility:* English language studies of laboratory-confirmed COVID-19 patients
63 which reported (a) prevalence of bacterial coinfection and/or (b) prevalence of antibiotic
64 prescribing with no restrictions to study designs or healthcare setting

65 *Participants:* Adults (aged ≥ 18 years) with RT-PCR confirmed diagnosis of COVID-19,
66 regardless of study setting.

67 *Methods:* Systematic review and meta-analysis. Proportion (prevalence) data was pooled
68 using random effects meta-analysis approach; and stratified based on region and study
69 design.

70 *Results:* A total of 1058 studies were screened, of which 22, hospital-based studies were
71 eligible, compromising 76,176 of COVID-19 patients. Pooled estimates for the prevalence of
72 bacterial co-infection and antibiotic use were 5.62% (95% CI 2.26 – 10.31) and 61.77% (CI
73 50.95 – 70.90), respectively. Sub-group analysis by region demonstrated that bacterial co-
74 infection was more prevalent in North American studies (7.89%, 95% CI 3.30-14.18).

75 *Conclusion:* Prevalence of bacterial coinfection in COVID-19 is low, yet prevalence of
76 antibiotic prescribing is high, indicating the need for targeted COVID-19 antimicrobial
77 stewardship initiatives to reduce the global threat of AMR.

78

79

80

81

82 **Keywords:** COVID-19, SARS-CoV-2, Bacterial Coinfection, Antibiotic Prescribing,
83 Antibiotics

84

85 1- Introduction

86

87 The first case of COVID-19 was reported in December 2019^[1, 2]. Since its emergence, the
88 novel severe acute respiratory coronavirus 2 (SARS-CoV-2) has resulted in a global
89 pandemic. As of January 14th 2022, a total of 318 million confirmed cases have been
90 reported, with 5.5 million confirmed deaths^[3]. The pandemic has overwhelmed healthcare
91 systems globally and proved to be a challenge to healthcare professionals in providing
92 optimum healthcare with limited evidence of effective treatment approaches certainly initially
93 with potential treatments including hydroxychloroquine, lopinavir/ritonavir and remdesivir
94 subsequently found to have limited impact in reducing morbidity and mortality in
95 hospitalised patients in large clinical trials^[4, 5]. In fact in the initial studies only
96 dexamethasone was shown to reduce mortality among patients with COVID-19 who were
97 receiving either invasive mechanical ventilation or oxygen alone^[6].

98

99 Alongside concerns with misinformation concerning potential treatments for patients with
100 COVID-19 including hydroxychloroquine and the subsequent impact on morbidity, mortality
101 and costs^[7, 8], the presence of bacterial co-infection in COVID-19 has been a widespread
102 concern amongst healthcare professionals due to overlapping clinical features with bacterial
103 pneumonia^[9], and the increased risk of morbidity and mortality associated with bacterial co-
104 infections^[10]. The presence of bacterial co-infection had been observed during previous viral
105 pandemics including the 1918 influenza pandemic and the 2009 influenza A (H1N1)
106 pandemic^[11, 12], with *S. pneumoniae*, β -hemolytic streptococci, *H. influenzae*, and *S. aureus*,
107 being the most common causative pathogens of respiratory tract infections^[13]. During winter
108 months influenza-associated bacterial infections may account for up to 30% of community
109 acquired pneumonia cases (CAP)^[14]. Nevertheless, other respiratory viruses such as Middle
110 East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-1 have reported a very
111 low prevalence of bacterial co-infection amongst infected patients^[15, 16] potentially
112 attributable to the comparatively small number of cases reported^[17].

113

114 Concerns regarding bacterial co-infection in COVID-19 patients has led to widespread use of
115 antibiotics empirically in both hospital and community settings^[18-22]. The significant increase
116 in antibiotic prescribing during the pandemic challenges antimicrobial stewardship
117 programmes and risks emergence of multi-drug resistant bacteria^[23-25], with their associated
118 impact on morbidity, mortality and costs^[26-29].

119

120 Prior meta-analyses suggest a bacterial coinfection prevalence of <4% - 8% in patients with
121 COVID-19, nonetheless, these studies included a small number of patients^[9, 30-32]. The
122 prevalence of antibiotic prescribing in patients with COVID-19 was 74.6%, reported in a
123 prior meta-analysis, which included literature mostly from Asia^[33]. Consequently, this review
124 aims at building on these publications through identifying the prevalence of bacterial co-
125 infection, and the prevalence of antibiotic use in patients with COVID-19 across multiple
126 countries and regions to guide future prescribing. This includes reducing the inappropriate
127 use of antimicrobials during the COVID-19 pandemic where inappropriate use is a potential
128 driver of antimicrobial resistance (AMR)^[24, 25, 34]

129 **2- Method**

130

131 *Search Strategy*

132

133 Electronic databases were systematically searched for published literature reporting bacterial
134 coinfection and/or antibiotic use in patients with COVID-19. The databases searched
135 included OVID MEDLINE, OVID EMBASE, Cochrane library and MedRxiv, with articles
136 published between December 2019 and 29th June 2021. The search terms and keywords used
137 included terms related to “COVID-19”, “Coinfections” and “Antibiotics” (*Appendix 1*). The
138 results of the search conducted were imported into Covidence online software for systematic
139 reviews, in which duplicate publications were removed. Reporting was based on the Preferred
140 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for
141 systematic reviews. The study protocol was registered in the international register of
142 systematic reviews, PROSPERO, under the following ID: CRD42021261734

143

144 *Study Selection*

145

146 Two reviewers (FA and ON) independently screened titles and abstracts and read full texts to
147 assess if they met the pre-set inclusion criteria, disputes were settled by third a reviewer
148 (AK). All English language articles, irrespective of their primary outcomes, reporting
149 bacterial coinfection rate and/or antibiotics use in, laboratory-confirmed (via Reverse
150 transcription polymerase chain reaction (RT- PCR)), COVID-19 human adult patients (≥ 18
151 years) in all healthcare settings were included (Outpatients and Inpatients). Studies in which
152 patients with suspected COVID-19, based on clinical symptoms and not laboratory confirmed
153 RT-PCR, were excluded. No restrictions to study design were applied. Case reports, case
154 notes, editorials, letters, systematic review, meta-analysis and qualitative studies were
155 excluded. Abstract only publications with no full text were also excluded.

156

157 Non-peer reviewed/ Pre-prints publications on MedRxiv were also included if the papers
158 contained relevant information regarding the topic of interest.

159

160

161 *Data Extraction and quality assessment*

162

163 Data was extracted into a standardised collection form that was created using Microsoft Excel
164 2016, by reviewers FA and ON. Data collected for information regarding the demographics
165 of the studies included the following variables: first author; publication year; country of
166 publication; study design (Retrospective, prospective, RCTs etc...); is the study multicentre;
167 study setting (Community, hospital, mixed etc...); if the study was peer-reviewed; number of
168 positive COVID-19 patients; proportion of male population; and the average age. Data was
169 collected for the following variables: prevalence of bacterial coinfection (defined as a
170 bacterial coinfection within 48 hours of positive COVID-19 diagnosis and hospital
171 admission), studies looking into super-infection and/or secondary-infection (occurring at 48
172 hours of hospital admission), were not included; and prevalence of antibiotic use among
173 COVID-19 patients. The following information, if reported, was also collected: bacterial
174 species isolated; the prevalence of most common bacteria; most common site of infection of


175 bacterial infection; clinical outcomes of co-infected patients; antibiotic class prescribed;
176 timing of antibiotic initiation in relation to COVID-19 onset and clinical outcomes of patients
177 prescribed antibiotics. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of
178 the observational studies included in the review^[35].
179
180

181 ***Data Synthesis, sensitivity analysis and publication bias***
182

183 The two primary outcomes were the prevalence of bacterial coinfection in COVID-19
184 patients and the prevalence of antibiotics use in COVID-19 patients. Further sub-group
185 analysis was conducted based on studies' region/continent and design. Proportion
186 (prevalence) outcome data across all studies were pooled using a random effect meta-analysis
187 with Freeman and Tukey method^[36]. Results were presented using forest plots, to
188 demonstrate the studies' effect size, and 95% confidence intervals (CI). Heterogeneity was
189 assessed using I^2 statistic. A value below 40% was considered to be low heterogeneity, 30 –
190 60% was considered to be moderate heterogeneity, 50-90% was substantial, and 75-100% is
191 considerable heterogeneity^[37]. Publication bias was assessed through Funnel plots followed
192 by Egger's asymmetry test^[38]. All analyses were carried out using STATA/BE 17.0 for
193 Windows (64-bit x 86-64) using the *Metaprop* command package.
194

195 **3- Results**
196

197 A total of 1183 studies were identified and 125 duplicates were removed. A total of 1058
198 studies were screened for title and abstract, 81 were screened by full-text screening and 22
199 studies were eligible for inclusion in the final analysis²⁴⁻⁴⁵ (**figure 1**). Prevalence of bacterial
200 coinfections was reported in 20 of the 22 studies included, whilst prevalence of antibiotics
201 use was reported in 18 studies only (**table 1**).
202
203



204
205 **Figure 1.** Study flow diagram based on PRISMA guidelines
206

Author, Year	Country	Study Design	Multicentre? (Y/N)	Study Setting	Peer-reviewed? (Y/N)	Quality Rating	COVID-19 Patients, n	Male, n (%)	Age (SD/IQR)	Bacterial Coinfection, n (%)	Most common Bacteria, N (%)	Antibiotic Use, N (%)	Antibiotic Class (most common)
1. Puzniak L, 2021 ^[39]	USA	Retrospective Cohort	Y	Hospital	Y	Good	17003	9026 (53)	61.7 (18)	2889 (16.99) (55.17)	<i>Enterobacteriales</i> , 1594	11562 (68)	Cephalosporins
2. Wang L, 2020 ^[40]	UK	Retrospective Cohort	Y	Hospital	Y	Good	1396	903 (65)	67.4 (16.2)	37(2.65)	<i>E. Coli</i> , 6 (16.22)	36 (2.58)	
3. Michael S, 2020 ^[41]	USA	Retrospective Cohort	Y	Hospital	Y	Good	73	35 (48)				27 (36.99)	NR
4. S. Hughes, 2020 ^[42]	UK	Retrospective Cohort	Y	Hospital	Y	Good	836	519 (62)	69 (55-81)	27 (3.23)	<i>S. aureus</i> , 4 (14.81)		
5. Contou D, 2020 ^[43]	France	Retrospective Cohort	N	Hospital	Y	Good	92	73 (79)	61 (55-70)	26 (28.26)	<i>S. aureus</i> , 10 (38.46)	39 (42.39)	Cephalosporins
6. Cheng, L, 2020 ^[44]	China	Retrospective Cohort	Y	Hospital	Y	Good	147	85 (58)	36 (24-54)	4 (2.72)		52 (35.37)	Cephalosporins
7. Neto A G M, 2020 ^[45]	USA	Retrospective Cohort	N	Hospital	Y	Good	242	123 (51)	66 (14.75)	46 (19.01)	<i>E. Coli</i> , 12 (26.09)	162 (66.94)	Cephalosporins
8. Lardaro T, 2020 ^[46]	USA	Retrospective Cohort	Y	Hospital	Y	Good	542	269 (50)	62.8 (16.5)	20 (3.69)	<i>S. aureus</i> , 7 (35)		
9. Chen S, 2020 ^[47]	China	Retrospective Cohort	N	Hospital	Y	Good	408	196 (48)	48 (34-60)	25 (6.13)	<i>mycoplasma pneumonia</i> , 13 (52)	60 (14.71)	NR
10. Baskar V, 2021 ^[48]	UK	Retrospective Cohort	Y	Hospital	Y	Good	254	164 (65)	59 (49-69)	14 (5.51)	<i>S. aureus</i> , 4 (28.57)		
11. Russell C D, 2021 ^[49]	UK	Prospective Cohort	Y	Hospital	Y	Good	48902	28116 (58)	74 (59-84)	318 (0.65)	<i>E. Coli</i> , 64 (20.13)	39528 (80.83)	Penicillin/B-lactams
12. Lehmann C J, 2021 ^[50]	USA	Retrospective Cohort	N	Hospital	Y	Poor	321	155 (48)	60 (17)	7 (2.18)	<i>S. aureus</i> , 2 (28.57)	222 (69.16)	NR
13. Vaughn V, 2021 ^[51]	USA	Retrospective Cohort	Y	Hospital	Y	Good	1705	885 (52)	64.7 (53-77)	59 (3.46)		965 (56.6)	Cephalosporins
14. Miao Q, 2021 ^[52]	China	Retrospective Cohort	N	Hospital	Y	Good	323			17 (5.26)	<i>Klebsiella pneumonia</i> , 11 (64.71)		
15. Karami Z, 2020 ^[53]	Netherlands	Retrospective Cohort	Y	Hospital	Y	Good	925	591 (64)	70 (59-77)	7 (0.76)	<i>S. aureus</i> , 4 (57.14)	556 (60.11)	Cephalosporins
16. Garcia-Vidal C, 2021 ^[54]	Spain	Retrospective Cohort	N	Hospital	Y	Good	989	552 (56)	62 (48-74)	31 (3.13)	<i>Streptococcus pneumonia</i> , 12 (38.71)	917 (92.72)	Macrolide
17. Crotty M P, 2020 ^[55]	USA	Prospective Cohort	Y	Hospital	N	Good	289		58.6 (14.4)	25 (8.65)	<i>S. aureus</i> , 5 (20)	271 (93.77)	NR
18. Wei W, 2020 ^[56]	USA	Prospective Cohort	N	Hospital	N	Good	147	87 (59)	52			87 (59.18)	Cephalosporins
19. Karaba S, 2020 ^[57]	USA	Prospective Cohort	Y	Hospital	Y	Good	1016	543 (53)	62 (48-74)	53 (5.22)		717 (70.57)	NR
20. Martin A, 2020 ^[58]	USA	Retrospective Cohort	Y	Hospital	N	Good	208	105 (51)	69 (60-80)	24 (11.54)	<i>S. aureus</i> , 5 (20.83)	172 (82.69)	Cephalosporins
21. Rothe K, 2021 ^[59]	Germany	Retrospective Cohort	N	Hospital	Y	Good	140	90 (64)	63.5 (17-99)	3 (2.14)		116 (82.86)	Penicillin/B-lactams
22. Asmarawati T P, 2020 ^[60]	Indonesia	Retrospective Cohort	N	Hospital	Y	Good	218	120 (55)	52.45 (14.44)	13 (5.96)	NR	164 (75.23)	Quinolones

Table 1. Summary of study and patients' characteristics

207 **Study characteristics**

208

209 Retrospective cohort studies accounted for the majority of the studies involved (n = 18, 81%),
210 whilst prospective cohort studies accounted for the remaining (n=4, 18%). Of the 22 studies
211 included, 3 (13%) studies were pre-prints [55, 56, 58], whilst the remaining (n=19, 86%) were
212 peer-reviewed. A total of 13 (59%) studies were conducted in multicentre settings, whilst the
213 remainder (n=9, 40%) were conducted in single centre settings. All of the studies included
214 were conducted in hospital settings, whether it be in a normal, isolation or an intensive care
215 ward. Twenty one out of the 22 studies have been classified as a “Good” rating during the
216 quality assessment process.

217

218 **Geographical distribution**

219

220 The majority of the studies included in the review took place in the United States of America
221 (USA) (n=10, 45%), followed by the United Kingdom (UK) (n=4, 18%), China (n=3, 14%)
222 and 1 study each in France, Germany, Indonesia, The Netherlands and Spain. Continent-wise,
223 10 (45%) studies were from North America, 8 (36%) from Europe and 4 (18%) were from
224 Asia.

225

226 **Patients Characteristics**

227

228 A total of 76,176 adult patients with RT-PCR confirmed COVID-19 were included from 22
229 studies, with studies by Russell *et al*[49] (UK, 48,902 patients) and Puzniak *et al* [39] (US,
230 17,003 patients) comprising 86.5% of the overall study population. The mean age of patients,
231 was 61 years (IQR 59-67, range 36-74) and mean proportion of male subjects was 54% (IQR
232 50-63).

233

234 The most commonly used class of antibiotics were the cephalosporins (8 out of 18 studies),
235 with 7 out of 18 of the studies reporting that antimicrobial use was initiated on admission.

236

237 **Meta-analysis of prevalence of bacterial coinfection in COVID-19 patients**

238

239 A total of 20 studies of the 22 studies included in this review, comprising of 75,956 (99.7%)
240 of the overall study population, investigated bacterial co-infection. Of which, only 3,645
241 (4.7%) patients were reported to have a confirmed diagnosis of bacterial co-infection. The
242 random effects meta-analysis of all combined studies estimated that the prevalence of
243 bacterial coinfection in COVID-19 patients was 5.62% (95% CI 2.26 – 10.31), with an I^2
244 value of 99.69%, indicating considerable heterogeneity (*Figure 2*).


245

246 Of all the 20 studies (90%) reporting on bacterial coinfection, the most commonly reported
247 bacterial organism was *S. aureus* (n=8, 40%), followed by *E.coli* (n=3, 15%). The most
248 common source of bacterial coinfection was respiratory (n=10, 50%), followed by blood
249 (n=2, 10%) and urine (n=2, 10%).

250

251

252



253

Figure 2. Prevalence of Bacterial coinfection


254

255

256 **Bacterial coinfection by Region**

257

258 The prevalence of bacterial coinfection was highest in North America (7.89%, 95% CI 3.30-
259 14.18), followed by Asia (5.3%, 95% CI 4.03 – 6.73), with Europe having the lowest
260 prevalence (3.57%, 95% CI 1.72 -6) (**Figure 3**). Heterogeneity was considerable in both
261 North America and Europe, $I^2 = 98.89\%$ and 96.75% respectively. Studies in Asia had low
262 heterogeneity with an I^2 value of 0%.
263



264

Figure 3. Prevalence of Bacterial coinfection by region

265

266

Bacterial coinfection by study design

267

268


269 Retrospective cohort studies had the highest prevalence of bacterial coinfection (5.92%, 95%
270 CI 2.79 – 10.07), whilst prospective cohort studies had a prevalence of 3.97% (95% CI 0.38,
271 10.92) (**Figure 4**). Heterogeneity was considerable in both retrospective and prospective, $I^2 =$

272 98.88% and 98.62% (**Appendix Fig. A**) respectively.

273

274

275



276

Figure 4. Prevalence of Bacterial coinfection by study design

277

278

279 **Meta-analysis of antibiotic use in COVID-19 patients**

280


281 Antibiotic use was reported in 55,653 of the total 76,176 patients included in this review,
282 with 18 studies (81%) reporting antibiotic use in COVID-19 patients. The random effects
283 meta-analysis of all combined studies have estimated a prevalence of 61.16% (CI 50.95 –
284 70.90) of antibiotic prescribing in COVID-19, with an I^2 value of 99.77%, indicating
285 considerable heterogeneity (**Figure 5**).

286

287

288

289



290

Figure 5. Antibiotic use

291
292

293 **Antibiotic use by region**

294


295 North America had the highest antibiotic use in COVID-19 patients per region (68.84%, 95%
296 CI 62.27 – 75.05), followed by Europe (60.01%, 95% CI 25.50- 89.67), with Asia having the
297 lowest prevalence of antibiotic use (40.81%, 95% CI 7.75 – 79.65) (**Figure 6**). Heterogeneity
298 was considerable across all with studies in Europe being the most heterogeneous ($I^2 =$
299 99.91%), followed by Asia ($I^2 = 99.18\%$) (**Appendix Fig. B**), followed by North America (I^2
300 = 97.28%).

301

302

303

304



305

Figure 6. Antibiotic use by region

306

307

308 *Antibiotic use by study design*

309


310 Prospective cohort studies had the highest estimate of antibiotic prescribing prevalence
311 (77.83%, 95% CI 68.09 – 86.23), followed by retrospective cohort studies (56.02%, 95% CI
312 39.40 – 71.97) (**Figure 7**). Heterogeneity was considerable in both Retrospective and
313 Prospective cohort studies, with I^2 value of 99.72% and 97.82%, respectively.

314

315

316

317



318

Figure 7. Antibiotic use by study design

319

Bias assessment

320

321

322

323

As detected by the funnel plots generated (**Figure 8**), there was no evidence of publication bias. This is further supported by the objective results (p-values) obtained through Egger's asymmetry test for studies in both prevalence of bacterial coinfection and antibiotic use, p-values were 0.43 and 0.59.

324

325

326


327

328

329

330 ??

331



332

333 **Figure 8.** Funnel plots illustrating the assessment of publication bias for each primary
334 outcome

335

336 4- Discussion

337

338 This systematic review and meta-analysis aimed at determining the prevalence of bacterial
339 coinfection and antibiotic use in COVID-19 patients. The prevalence of bacterial coinfection
340 amongst COVID-19 patients was 5.62% (95% CI 2.26 – 10.31) whilst, the use of antibiotic
341 agents amongst COVID-19 patients was 61.77% (CI 50.95 – 70.90). To the best of the
342 authors' knowledge, this is the first meta-analysis to investigate both outcomes at once as
343 well as break the findings down by Region to provide future guidance.

344

345 With regards to bacterial coinfection in COVID-19 patients, the findings in this review is
346 consistent with those of previously published studies and smaller systematic reviews
347 addressing this issue (Range <4% - 8%)^[9, 30-32]. Bacterial coinfection prevalence were low
348 across all included studies, with the exception to Contou *et al*, Neto *et al* and Puzniak *et al*
349 in which the reported prevalence rates were 28%, 19% and 16% respectively^[39, 43, 45].

350 High prevalence rates reported by Contou *et al* can be attributed to the study setting, which
351 was the ICU. Symptomatic patients admitted to the ICU were tested for COVID-19 and for
352 bacteriological pathogens afterwards; consequently, potentially reporting higher prevalence
353 of bacterial coinfection. Nonetheless, Contou D *et al* clearly differentiated in their study
354 design between coinfections and nosocomial infections. Positive microbiological samples
355 conducted within the first 48 hours of admission were labelled as coinfection, whilst positive
356 microbiological samples after 48 hours were considered to be nosocomial ICU-acquired
357 infections^[43].

358

359 Urinary tract infections (UTIs) were the most prevalent source of bacterial coinfection (57%)
360 as reported by Neto et al^[45]. The authors attributed the high UTI rate to the lack of a fixed

361 defining clinical characteristics of bacterial coinfection and to high risk factors for UTIs
362 amongst the study population, e.g. elderly hospitalised female patients and diabetic patients.
363 High bacterial coinfection prevalence rates (16%) were reported by Puznik *et al*^[39], the
364 second largest study included in this review, when compared to the low prevalence rates
365 reported by Russell *et al*^[49] (0.65%), the largest study in the review. This may be due to a
366 number of factors. These include the frequency of microbiological investigations, in which,
367 investigation rates were higher in the study of Puznik *et al*. Interpretation of microbiological
368 results in which gram-negative bacteria in sputum samples of non-ventilated patients were
369 taken which may have over-estimated significance of bacterial coinfection^[39].
370

371 The analyses conducted around bacterial coinfection in COVID-19 patients suggests that
372 bacterial coinfection prevalence rates are lower than seen in previous viral pandemics. During
373 the 2009 swine flu pandemic, up to 55% of mortalities were as a result of bacterial
374 pneumonia^[46]. Previous pandemics have also reported that *S. pneumoniae*, *β-hemolytic*
375 *streptococci*, *H. influenzae*, and *S. aureus* were the most commonly identified bacterial co-
376 pathogens^[13]. In this review, *S. aureus* has been the most identified bacterial co-pathogen.
377

378 This review also identified very high antibiotic use in COVID-19 patients, which is consistent
379 with previous reviews including those of Langford *et al* (2021)^[33], which reported a
380 prevalence of 74.6% (95% CI 68.3-80.0%). Differences between the results seen in this
381 review and the review of Langford *et al* may be attributed to the fact that the latter review
382 also included case series with ≥10 patients. This can potentially be attributed to the time
383 period of the pandemic in which the studies were conducted. There was scarceness of cohort
384 studies in the review of Langford *et al* (2021)^[33], which is different to our study. This review
385 also included a wider selection of nations in addition to a larger number of patients.
386

387 The increase in antibiotic use observed during this pandemic might have impacted and
388 setback antimicrobial stewardship (AMS) efforts globally, especially in regions where AMS
389 programmes are just starting as seen in Africa with previous knowledge and resource issues
390^[61-63]. This is starting to change in Africa with a growing number of AMS activities to
391 address identified concerns^[64-66]. However, remarkably, in certain regions globally,
392 specifically in Europe, there was a decline in antibiotic use overall in 2020, despite high
393 antibiotic use in COVID-19 positive patients. This can potentially be attributed to a number
394 of factors including social distancing measures and reduction in medical activities^[67-69].
395 Nonetheless, inappropriate use of antibiotics during COVID-19 is a potential driver of the
396 silent AMR pandemic^[24, 70]. However, with current changes observed in global human
397 behaviour, relating to personal hygiene, and increased interest in infection control since the
398 emergence of this pandemic, we should see a rise in AMS activities globally^[71].
399

400 Sub-group analysis based on the key regions demonstrated that the prevalence of reported
401 bacterial coinfection was higher in North America followed by Asia and Europe at 7.89%,
402 5.30% and 3.57%, respectively. Antibiotic use was also higher in North America (68.84%),
403 followed by Europe (60%) and Asia (40.81%). Our hypothesis suggests that the reason for
404 higher prevalence of bacterial coinfection and antibiotic use in North America is due to the
405 presence of larger number of studies and patients from the region in this review, in addition
406 to possibly higher rates of microbiology investigation and over interpretation of microbiology

407 results. Nevertheless, studies from Asia are reporting high use of antibiotics including the
408 study of Hassan *et al*, which reported extremely high use of antibiotics (92%) in COVID-19
409 patients^[72], however, this study was not included in our meta-analysis as it has not met our
410 inclusion criteria. We are also aware of more recent studies in Asia reporting high rates since
411 our analysis^[22, 73].

412
413 In this review, investigating regional distribution of co-infection and antibiotic use was key.
414 Its significance is directly correlated to the fact that antimicrobial use varies considerably
415 across regions, albeit some convergence^[74]. It is quite apparent that high antibiotic
416 consumption is common in low- and middle-income countries (LMICs) in contrast to high-
417 income countries (HICs)^[74]. In addition, AMR rates vary considerably across countries and
418 regions, with high AMR rates quite evident in regions such as South Asia and Sub-Saharan
419 Africa, therefore, it was practical, in this review, to breakdown antibiotic usage rates by
420 region^[75, 76].

421
422 In terms of study design, sub-group analysis has demonstrated that retrospective studies had
423 higher prevalence of bacterial coinfection than prospective ones at 5.92% vs 3.97%
424 respectively. Whilst, on the other hand, antibiotic use was higher in prospective than
425 retrospective studies, 77.83% vs 56.02%, respectively. The main hypothesis that might
426 explain these variations in prevalence from the main meta-analyses is the study design itself.
427 Prospective studies had well-defined processes to determine bacterial coinfection in COVID-
428 19 patients, such as pre-defined clinical characteristics that prompt microbiological
429 sampling^[49]; hence likely lower bacterial coinfection rates but higher justifiable antibiotic
430 use.

431
432 Despite having 10 out of 22 studies included in this review published in 2021, all the studies
433 included have been conducted mainly in the first few months of the pandemic (February and
434 April 2020) with the exception of one study conducted in June 2020^[60]. The results from this
435 review demonstrates that there is insufficient evidence supporting considerable empiric
436 antibiotic prescribing in COVID-19 patients due to a low prevalence of bacterial coinfection.
437 Nonetheless, antibiotics use was high mirroring the findings in other reviews. As the
438 pandemic evolves, and new COVID-19 specific therapeutics come into clinical practice, it
439 will be important to assess their impact on antibiotic use. The early phase of the pandemic
440 from which most of the published studies to date relate has been characterised by a lack of
441 specific COVID-19 therapies and it may be as treatment options become available, and the
442 understanding of the low prevalence of bacterial co-infection becomes more established, that
443 there will be less reliance or defaulting to antibiotic prescribing. We will be following this up
444 in future studies.

445
446 **Strengths and Limitations**
447
448 We believe the key strengths of this review included a comprehensive search strategy
449 spanning several databases, including both pre-prints and peer-reviewed studies, resulting in
450 22 studies being included, representing over 76,000 patients.
451

452 However, we are aware that this review was not without limitations. During the screening
453 process, a significant number of studies have been excluded as they did not meet the
454 inclusion criteria. The majority of the excluded studies included non-lab confirmed COVID-
455 19 patients, therefore, bacterial coinfection and antibiotic use may be under- or over-reported.
456 Disproportionate representation from North America and failure to include studies from
457 regions other than Europe and Asia can also limit the generalizability of the results to other
458 regions impacted by COVID-19. Additionally, the majority of studies included were
459 conducted within the first 6 month of pandemic. Consequently, data included might not be up
460 to date, which again, can compromise the generalizability of the results. Notably, the
461 emergence of new variants, updated treatment regimens and variations in measures for
462 SARS-CoV-2 testing, might impact the prevalence of bacterial coinfection and antibiotic
463 use^[77]. In addition, the majority of studies included in the meta-analyses were retrospective
464 studies with their inherently associated bias and limitations.

465

466 Alongside this, determining the appropriateness and justifiable need of antibiotic therapy,
467 which is likely to be higher in prospective studies in comparison to retrospective studies, was
468 not possible, as studies have mainly reported the number of patients prescribed antibiotics.
469 Information such as indications, initiation timing and duration of antibiotic could assist in
470 determining future appropriateness. Diagnostic tests and measures used to determine
471 bacteriological infections were also under-reported. This is crucial to determine whether the
472 infection is a true infection or bacterial colonisation.

473

474 In addition 3 (13%) of the 22 studies included in this review were non-peer reviewed, which
475 might raise concerns regarding their quality^[55, 56, 58]. However, one of these studies is now
476 published, so it is unlikely to be of low quality^[58]. The remaining two, despite not being
477 published, have still attained a “good” quality rating using the NOS, in addition, both studies
478 weighted in the forest plot were small, and therefore unlikely to affect the overall results

479

480 Future reviews and studies should aim at diversifying study regions, and to include or
481 conduct studies that are more up to date. Studies should also include data on the
482 appropriateness of antibiotic therapy, diagnostic tests and measures used to determine the
483 infection. However, despite these limitations, we believe the findings give good guidance
484 regarding the need to improve the rationality of antibiotic prescribing in patients with
485 COVID-19 to reduce the occurrence of AMR within facilities.

486

487 ***Conclusion***

488

489 This study demonstrates that the prevalence of bacterial coinfection amongst COVID-19
490 patients was low, 5.62%, nevertheless, antibiotics use amongst COVID-19 patients was high
491 (61.77%). The findings of this study encourage a more rational approach to antibiotics
492 prescribing in COVID-19 patients, an approach based on laboratory-confirmed diagnosis of
493 coinfection, rather than clinical, advocating for more antimicrobial stewardship (AMS). We
494 know that antimicrobial stewardship programmes have been successfully instigated across
495 countries including LMICs, and we will be looking to build on this.

496

497 **Statements and Declarations**

498 **Funding**

499 *The authors declare that no funds, grants, or other support were received during the
500 preparation of this manuscript*

501

502 **Competing Interests**

503 *The authors have no relevant financial or non-financial interests to disclose*

504

505 **Author Contributions**

506 *Data collection and analysis were performed by Faisal Alshaikh, Oula Sindi and Amanj
507 Kurdi. The first draft of the manuscript was written by Faisal Alshaikh and all authors
508 commented on previous versions of the manuscript. All authors read and approved the final
509 manuscript*

510

511 **Data Availability**

512 *All data generated or analysed during this study are included in this published article*

513

514 **Ethics approval**

515 *Not applicable*

516

517 **Consent to participate**

518 *Not applicable*

519

520 **Consent to publish**

521 *Not applicable*

522 **References**

523

- 524 1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in
525 Wuhan, China, of novel coronavirus–infected pneumonia. *New England journal of medicine*.
526 2020.
- 527 2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus
528 disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the
529 Chinese Center for Disease Control and Prevention. *Jama*. 2020;323(13):1239-42.
- 530 3. WHO. WHO Coronavirus (COVID-19) Dashboard 2022, January 02 [Available from:
531 <https://covid19.who.int/>.
- 532 4. Harris M, Bagozzi D. WHO discontinues hydroxychloroquine and lopinavir/ritonavir
533 treatment arms for COVID-19. *World Heal Organ News Release*. 2020.
- 534 5. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of
535 hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a
536 multi-centre, randomized, controlled trial. *MedRxiv*. 2020.
- 537 6. Group RC. Dexamethasone in hospitalized patients with Covid-19. *New England
538 Journal of Medicine*. 2021;384(8):693-704.
- 539 7. Abena PM, Declerdt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings. *The American journal of tropical medicine and hygiene*. 2020;102(6):1184-8.
- 543 8. Sefah IA, Ogunleye OO, Essah DO, Opanga SA, Butt N, Wamaitha A, et al. Rapid assessment of the potential paucity and price increases for suggested medicines and protection equipment for COVID-19 across developing countries with a particular focus on Africa and the implications. *Frontiers in pharmacology*. 2021;11:2055.
- 547 9. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. *Journal of Infection*. 2020;81(2):266-75.
- 549 10. Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. *Frontiers in microbiology*. 2017;8:1041.
- 551 11. Gupta RK, George R, Nguyen-Van-Tam JS. Bacterial pneumonia and pandemic influenza planning. *Emerging infectious diseases*. 2008;14(8):1187.
- 553 12. Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A (H1N1) virus. *Chest*. 2011;139(3):555-62.
- 556 13. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *The Journal of infectious diseases*. 2008;198(7):962-70.
- 559 14. Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. *Influenza and other respiratory viruses*. 2013;7:105-13.
- 561 15. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *The Lancet infectious diseases*. 2013;13(9):752-61.
- 565 16. Zahariadis G, Gooley TA, Ryall P, Hutchinson C, Latchford MI, Fearon MA, et al. Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: variable incidence of atypical bacteria coinfection based on diagnostic assays. *Canadian respiratory journal*. 2006;13(1):17-22.
- 569 17. Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, et al. Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. *Critical care medicine*. 2017;45(10):1683-95.

- 572 18. Grau S, Hernández S, Echeverría-Esnal D, Almendral A, Ferrer R, Limón E, et al.
573 Antimicrobial consumption among 66 acute care hospitals in Catalonia: impact of the
574 COVID-19 pandemic. *Antibiotics*. 2021;10(8):943.
- 575 19. Mustafa ZU, Salman M, Aldeyab M, Kow CS, Hasan SS. Antimicrobial consumption
576 among hospitalized patients with COVID-19 in Pakistan. *SN comprehensive clinical
577 medicine*. 2021;1-5.
- 578 20. Molla MMA, Yeasmin M, Islam MK, Sharif MM, Amin MR, Nafisa T, et al.
579 Antibiotic Prescribing Patterns at COVID-19 Dedicated Wards in Bangladesh: Findings from
580 a Single Center Study. *Infection Prevention in Practice*. 2021;3(2):100134.
- 581 21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
582 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
583 *The lancet*. 2020;395(10229):1054-62.
- 584 22. Chowdhury K, Haque M, Nusrat N, Adnan N, Islam S, Lutfor AB, et al. Management
585 of children admitted to hospitals across Bangladesh with suspected or confirmed COVID-19
586 and the implications for the future: a nationwide cross-sectional study. *Antibiotics*.
587 2022;11(1):105.
- 588 23. Caselli E. Hygiene: microbial strategies to reduce pathogens and drug resistance in
589 clinical settings. *Microbial Biotechnology*. 2017;10(5):1079-83.
- 590 24. Founou RC, Blocker AJ, Noubom M, Tsayem C, Choukem SP, Dongen MV, et al.
591 The COVID-19 pandemic: a threat to antimicrobial resistance containment. *Future Science
592 OA*. 2021(0):FSO736.
- 593 25. Hsu J. How covid-19 is accelerating the threat of antimicrobial resistance. *Bmj*.
594 2020;369.
- 595 26. Cassini A, Höglberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al.
596 Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-
597 resistant bacteria in the EU and the European Economic Area in 2015: a population-level
598 modelling analysis. *The Lancet infectious diseases*. 2019;19(1):56-66.
- 599 27. Hofer U. The cost of antimicrobial resistance. *Nature Reviews Microbiology*.
600 2019;17(1):3-.
- 601 28. Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, et al.
602 Strategies to improve antimicrobial utilization with a special focus on developing countries.
603 *Life*. 2021;11(6):528.
- 604 29. Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic
605 resistance in developing countries: a systematic review and meta-analysis. *PloS one*.
606 2017;12(12):e0189621.
- 607 30. Westblade LF, Simon MS, Satlin MJ. Bacterial Co-Infections in Coronavirus Disease
608 2019. *Trends in microbiology*. 2021.
- 609 31. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al.
610 Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid
611 review and meta-analysis. *Clinical Microbiology and Infection*. 2020.
- 612 32. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N.
613 Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other
614 pathogens: A systematic review and meta-analysis. *PloS one*. 2021;16(5):e0251170.
- 615 33. Langford BJ, So M, Raybardhan S, Leung V, Soucy J-PR, Westwood D, et al.
616 Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. *Clinical
617 Microbiology and Infection*. 2021.
- 618 34. Iwu CJ, Jordan P, Jaja IF, Iwu CD, Wiysonge CS. Treatment of COVID-19:
619 implications for antimicrobial resistance in Africa. *The Pan African Medical Journal*.
620 2020;35(Suppl 2).

- 621 35. Institute OHR. The Newcastle-Ottawa Scale (NOS) for assessing the quality of
622 nonrandomised studies in meta-analyses 2021 [Available from: The Newcastle-Ottawa Scale
623 (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
624 36. Freeman MF, Tukey JW. Transformations related to the angular and the square root.
625 The Annals of Mathematical Statistics. 1950;607-11.
626 37. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials:
627 an update. Contemporary clinical trials. 2007;28(2):105-14.
628 38. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other
629 sample size effects in systematic reviews of diagnostic test accuracy was assessed. Journal of
630 clinical epidemiology. 2005;58(9):882-93.
631 39. Puzniak L, Finelli L, Kalvin CY, Bauer KA, Moise P, De Anda C, et al. A multicenter
632 analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the
633 US with or without COVID-19. BMC infectious diseases. 2021;21(1):1-9.
634 40. Wang L, Amin AK, Khanna P, Aali A, McGregor A, Bassett P, et al. An
635 observational cohort study of bacterial co-infection and implications for empirical antibiotic
636 therapy in patients presenting with COVID-19 to hospitals in North West London. Journal of
637 Antimicrobial Chemotherapy. 2021;76(3):796-803.
638 41. Pulia MS, Wolf I, Schwei RJ, Chen D, Lepak AJ, Schulz LT, et al. Antibiotic
639 prescribing patterns for coronavirus disease 2019 (COVID-19) in two emergency
640 departments with rapid procalcitonin. Infection Control & Hospital Epidemiology.
641 2021;42(3):359-61.
642 42. Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal
643 coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a
644 UK secondary-care setting. Clinical Microbiology and Infection. 2020;26(10):1395-9.
645 43. Contou D, Claudinon A, Pajot O, Micaëlo M, Flandre PL, Dubert M, et al. Bacterial
646 and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French
647 ICU. Annals of intensive care. 2020;10(1):1-9.
648 44. Cheng LS-k, Chau SK-y, Tso EY-k, Tsang SW-c, Li IY-f, Wong BK-c, et al.
649 Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19:
650 experience from a single hospital cluster. Therapeutic Advances in Infectious Disease.
651 2020;7:2049936120978095.
652 45. Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy III R, et
653 al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. Journal of
654 medical virology. 2021;93(3):1489-95.
655 46. Lardaro T, Wang AZ, Bucca A, Croft A, Glober N, Holt DB, et al. Characteristics of
656 COVID-19 patients with bacterial coinfection admitted to the hospital from the emergency
657 department in a large regional healthcare system. Journal of Medical Virology.
658 2021;93(5):2883-9.
659 47. Chen S, Zhu Q, Xiao Y, Wu C, Jiang Z, Liu L, et al. Clinical and etiological analysis
660 of co-infections and secondary infections in COVID-19 patients: An observational study.
661 The Clinical Respiratory Journal. 2021.
662 48. Baskaran V, Lawrence H, Lansbury LE, Webb K, Safavi S, Zainuddin NI, et al. Co-
663 infection in critically ill patients with COVID-19: an observational cohort study from
664 England. Journal of medical microbiology. 2021;70(4).
665 49. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Woottton DG, et al. Co-
666 infections, secondary infections, and antimicrobial usage in hospitalised patients with
667 COVID-19 from the ISARIC WHO CCP-UK study: a prospective, multicentre cohort study.
668 2021.

- 669 50. Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN. Community-acquired
670 coinfection in coronavirus disease 2019: A retrospective observational experience. Clinical
671 Infectious Diseases. 2021;72(8):1450-2.
- 672 51. Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric
673 antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with
674 coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clinical Infectious
675 Diseases. 2021;72(10):e533-e41.
- 676 52. Miao Q, Ma Y, Ling Y, Jin W, Su Y, Wang Q, et al. Evaluation of superinfection,
677 antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19
678 patients: A cohort study in Shanghai. Journal of Microbiology, Immunology and Infection.
679 2021.
- 680 53. Karami Z, Knoop BT, Dofferhoff AS, Blaauw MJ, Janssen NA, van Apeldoorn M, et
681 al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of
682 hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in
683 The Netherlands. Infectious Diseases. 2021;53(2):102-10.
- 684 54. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N,
685 Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients
686 with COVID-19: a retrospective cohort study. Clinical Microbiology and Infection.
687 2021;27(1):83-8.
- 688 55. Crotty MP, Dominguez EA, Akins R, Nguyen AT, Slika R, Rahmazadeh K, et al.
689 Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in
690 hospitalized patients. medRxiv. 2020.
- 691 56. Wei W, Ortwine JK, Mang NS, Joseph C, Hall BC, Prokesch BC. Limited role for
692 antibiotics in COVID-19: scarce evidence of bacterial coinfection. Available at SSRN
693 3622388. 2020.
- 694 57. Karaba SM, Jones G, Helsel T, Smith LL, Avery R, Dzintars K, et al., editors.
695 Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a
696 multicenter study. Open forum infectious diseases; 2021: Oxford University Press US.
- 697 58. Martin AJ, Shulder S, Dobrzynski D, Quartuccio K, Pillinger KE. Rate of Antibiotic
698 Use and Associated Risk Factors in COVID-19 Hospitalized Patients. medRxiv. 2020.
- 699 59. Rothe K, Feihl S, Schneider J, Wallnöfer F, Wurst M, Lukas M, et al. Rates of
700 bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort
701 study in light of antibiotic stewardship. European Journal of Clinical Microbiology &
702 Infectious Diseases. 2021;40(4):859-69.
- 703 60. Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum
704 PA, et al. The clinical impact of bacterial co-infection among moderate, severe and critically
705 ill COVID-19 patients in the second referral hospital in Surabaya. F1000Research. 2021;10.
- 706 61. Fadare JO, Ogunleye O, Iliyasu G, Adeoti A, Schellack N, Engler D, et al. Status of
707 antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: findings and
708 implications. Journal of global antimicrobial resistance. 2019;17:132-6.
- 709 62. Kalungia AC, Mwambula H, Munkombwe D, Marshall S, Schellack N, May C, et al.
710 Antimicrobial stewardship knowledge and perception among physicians and pharmacists at
711 leading tertiary teaching hospitals in Zambia: implications for future policy and practice.
712 Journal of chemotherapy. 2019;31(7-8):378-87.
- 713 63. Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, Villegas MV, et al.
714 Antibiotic stewardship in low-and middle-income countries: the same but different? Clinical
715 microbiology and infection. 2017;23(11):812-8.
- 716 64. Sneddon J, Cooper L, Afriyie DK, Sefah IA, Cockburn A, Kerr F, et al. Supporting
717 antimicrobial stewardship in Ghana: Evaluation of the impact of training on knowledge and

- 718 attitudes of healthcare professionals in two hospitals. JAC-antimicrobial resistance.
719 2020;2(4):dlaa092.
- 720 65. D'Arcy N, Ashiru-Oredope D, Olaoye O, Afriyie D, Akello Z, Ankrah D, et al.
721 Antibiotic Prescribing Patterns in Ghana, Uganda, Zambia and Tanzania Hospitals: Results
722 from the Global Point Prevalence Survey (G-PPS) on Antimicrobial Use and Stewardship
723 Interventions Implemented. *Antibiotics*. 2021;10(9):1122.
- 724 66. Akpan MR, Isemin NU, Udoth AE, Ashiru-Oredope D. Implementation of
725 antimicrobial stewardship programmes in African countries: a systematic literature review.
726 *Journal of global antimicrobial resistance*. 2020;22:317-24.
- 727 67. Scotland HP. SONAAR report for 2020. NHS Scotland 2021 16 November 2021.
- 728 68. Agency UHS. English surveillance programme for antimicrobial utilisation and
729 resistance (ESPAUR) Report for 2020 to 2021. England; 2021. Contract No.: GOV-9892.
- 730 69. (ECDC) ECfDPaC. Surveillance of antimicrobial resistance in Europe, 2020 data.
731 2021.
- 732 70. Nusrat N, Haque M, Chowdhury K, Adnan N, Lutfor AB, Karim E, et al. Pilot study
733 on the current management of children with COVID-19 in hospitals in Bangladesh; findings
734 and implications. *Bangladesh Journal of Medical Science*. 2021;188-98.
- 735 71. Huttner B, Catho G, Pano-Pardo J, Pulcini C, Schouten J. COVID-19: don't neglect
736 antimicrobial stewardship principles! *Clinical Microbiology and Infection*. 2020;26(7):808.
- 737 72. Hassan M, Biswas M, Al Jubayer A, Rahman F, Akhtar Z, Das P, et al. Use of
738 Antimicrobials among Suspected COVID-19 Patients at Selected Hospitals, Bangladesh:
739 Findings from the First Wave of COVID-19 Pandemic. *Antibiotics*. 2021;10(6):738.
- 740 73. Kumar S, Haque M, Shetty A, Acharya J, Kumar M, Sinha VK, et al. Current
741 management of children with COVID-19 in hospitals in India; pilot study and findings.
742 *Advances in Human Biology*. 2021.
- 743 74. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global
744 increase and geographic convergence in antibiotic consumption between 2000 and 2015.
745 *Proceedings of the National Academy of Sciences*. 2018;115(15):E3463-E70.
- 746 75. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global
747 burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*. 2022.
- 748 76. Sriram A KE KG, Craig J, Balasubramanian R, Brar S et al. A global analysis of
749 antimicrobial resistance and its drivers. Center for Disease Dynamics, Economics & Policy.
750 Washington, DC; 2021 2021.
- 751 77. Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2
752 Variants, Vaccines and Therapeutic Strategies. 2021.
- 753
- 754

755 **Appendices**

756

757 *Appendix 1: Key search strategy*

758

759 **Embase (OVID)**

760

	Searches	Results
1	coronavirus disease 2019.ti,ab,kw.	25682
2	covid-19.ti,ab,kw.	130651
3	severe acute respiratory syndrome coronavirus 2.ti,ab,kw.	14082
4	1 or 2 or 3	134431
5	mixed infection.ti,ab,kw.	4870
6	co-infection.ti,ab,kw.	18590
7	5 or 6	23284
8	antibiotic agent.ti,ab,kw.	766
9	antimicrobial therapy.ti,ab,kw.	18563
10	antimicrobial activity.ti,ab,kw.	46766
11	antibacterial activity.ti,ab,kw.	46261
12	antiinfective agent.ti,ab,kw.	31
13	8 or 9 or 10 or 11 or 12	103731
14	7 or 13	126880
15	4 and 14	463
16	prevalence/	793668
17	Observational Studies/ or observational.ti,ab.	384858
18	prospective studies/ or retrospective studies/ or prospective.ti,ab. or retrospective.ti,ab.	2326072
19	randomized controlled trial/	665355
20	16 or 17 or 18 or 19	3703038
21	15 and 20	151
22	limit 21 to (human and yr="2019 -Current")	149
23	limit 22 to english language	147

761

762

763

764 **MedLine (OVID)**

765

	Searches	Results
1	COVID-19/	88096
2	Coronavirus Infections/	44949
3	SARS-CoV-2/	68317
4	covid*.ti,ab,kw.	134027
5	coronavirus*.ti,ab,kw.	68550
6	ncov*.ti,ab,kw.	1606
7	sars*.ti,ab,kw.	60031
8	severe acute respiratory syndrome coronavir*.ti,ab,kw.	16722
9	"2019 ncov*".ti,ab,kw.	1682
10	nCOV19*.ti,ab,kw.	9
11	SARSCoV2*.ti,ab,kw.	45
12	"sars cov2*".ti,ab,kw.	2059
13	"coronavirus 19*".ti,ab,kw.	290
14	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13	170734
15	Coinfection/	12379
16	coinfect*.ti,ab,kw.	15898
17	co-infect*.ti,ab,kw.	18471
18	"mixed infecti*".ti,ab,kw.	7718
19	"bacterial coinfect*".ti,ab,kw.	311
20	"bacterial co-infect*".ti,ab,kw.	365
21	15 or 16 or 17 or 18 or 19 or 20	44285
22	Anti-Bacterial Agents/	354528
23	Anti-Infective Agents/	56119
24	antimicrob*.ti,ab,kw.	184372
25	anti-microb*.ti,ab,kw.	4930
26	antiinfect*.ti,ab,kw.	798
27	anti-infect*.ti,ab,kw.	7984
28	antibact*.ti,ab,kw.	84949
29	anti-bact*.ti,ab,kw.	4701
30	antibiot*.ti,ab,kw.	372008
31	22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30	710470
32	21 or 31	751355
33	14 and 32	4117
34	prevalence/	311186
35	Observational Studies/ or Observational.ti,ab,kw.	203842
36	prospective studies/ or retrospective studies/ or prospective.ti,ab,kw. or retrospective.ti,ab,kw.	1880121
37	randomized controlled trial/	535869
38	34 or 35 or 36 or 37	2654657
39	33 and 38	836
40	limit 39 to (english language and humans and yr="2019 - 2022")	461

766 **Cochrane**

767

ID	Search	Hits
#1	MeSH descriptor: [COVID-19] this term only	398
#2	MeSH descriptor: [Severe Acute Respiratory Syndrome] this term only	358
#3	MeSH descriptor: [SARS-CoV-2] this term only	294
#4	(covid*):ti,ab,kw	5941
#5	(corona*):ti,ab,kw	65223
#6	(coronavirus*):ti,ab,kw	3372
#7	(coronavirus infect*):ti,ab,kw	2051
#8	("SARS-Co-V*"):ti,ab,kw	2144
#9	("severe acute respiratory syndrome coronavirus*"):ti,ab,kw	489
#10	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9	68000
#11	MeSH descriptor: [Coinfection] this term only	210
#12	MeSH descriptor: [Bacterial Infections] this term only	3191
#13	MeSH descriptor: [Respiratory Tract Infections] this term only	2323
#14	(coinfect*):ti,ab,kw	1606
#15	(co-infect*):ti,ab,kw	965
#16	("co infect*"):ti,ab,kw	1
#17	("mixed infection*"):ti,ab,kw	579
#18	("respiratory infection*"):ti,ab,kw	1323
#19	#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18	8180
#20	MeSH descriptor: [Anti-Bacterial Agents] this term only	11188
#21	MeSH descriptor: [Antibiotic Prophylaxis] this term only	1301
#22	MeSH descriptor: [Anti-Infective Agents] this term only	2715
#23	(antibiotic*):ti,ab,kw	32360
#24	(antimicrobial*):ti,ab,kw	7832
#25	("antimicrobial drug*"):ti,ab,kw	82
#26	("antibiotic drug*"):ti,ab,kw	55
#27	("antibiotic agent*"):ti,ab,kw	2527
#28	("empirical antibiotic*"):ti,ab,kw	166
#29	("prophylactic antibiotic*"):ti,ab,kw	635
#30	#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29	42620
#31	#19 OR #30	47991
#32	#10 AND #31	822
#33	#32 with Cochrane Library publication date Between Nov 2019 and Jun 2021	392
#34	#33 in Cochrane Reviews, Trials	392

768


769 **MedRXiv**

770

771 Full text or abstract or title "covid-19 AND (Antibiotic OR Coinfection)" (match whole all)
772 and posted between "01 Dec, 2019 and 14 Jun, 2021" Reuslts: **182**

773

774




775

776

777

Fig a. Prevalence of Bacterial coinfection in Prospective Cohort Studies



778

779

Figure b. Prevalence of antibiotic use in Asia